Stereotaxis to Present at Three Investor Conferences in March
February 26 2020 - 4:06PM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced that David Fischel, Chairman and CEO, will present at
three investor conferences in March 2020.
- Cowen and Company 40th Annual Health Care Conference Mr.
Fischel will present an overview of Stereotaxis business on
Monday, March 2, 2020, 4:50 - 5:20 pm EST, will
participate in a breakout session immediately afterwards, and will
be available that day for one-on-one meetings.
- Oppenheimer 30th Annual Healthcare ConferenceMr. Fischel will
present an overview of Stereotaxis business on Tuesday,
March 17, 2020 from 4:30 - 5:00 pm EST, and will be
available that day for one-on-one meetings.
- BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools ConferenceMr. Fischel will be available for one-on-one
meetings with investors on Wednesday, March 18,
2020.
“We appreciate the invitations to these
conferences and look forward to sharing with the investment
community Stereotaxis’ differentiated technology, clinical value,
and growth strategy.” says Mr. Fischel. One-on-one meetings with
Mr. Fischel can be arranged through registration with these
conferences.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024